peptide-safety-incident
peptide-safety-incident
The prediction
By 2027-03-31, a top-5 US news outlet (NYT, WSJ, CNN, NPR, WaPo) publishes a major feature on peptide injuries, contamination, or deaths sourced from compounded/gray-market products
Adoption at current velocity plus 40 percent contamination rate plus minimal regulation equals statistical certainty of adverse event. Media narrative arc typically runs hype-phase to backlash-phase within 12-18 months. Already have safety-focused coverage seeding (NPR Feb 2026, UNSW April 2026). Counter-narrative ~30%: FDA enforcement of gray-market sellers tightens fast enough to prevent headline-grade incident; industry self-regulation via compounders catches contamination early.
Trajectory
- 19 April 2026 · created70%signal strength 61
Adoption at current velocity plus 40 percent contamination rate plus minimal regulation equals statistical certainty of adverse event. Media narrative arc typically runs hype-phase to backlash-phase within 12-18 months. Already have safety-focused coverage seeding (NPR Feb 2026, UNSW April 2026). Counter-narrative ~30%: FDA enforcement of gray-market sellers tightens fast enough to prevent headline-grade incident; industry self-regulation via compounders catches contamination early.
- 2026-04-19 07:00 UTC · Ra run· flagged70%0· signal 63
No new evidence today but reference-class widened to include NMN/NAC/ConsumerLab creatine/2008 heparin analogues. Base rate likely closer to 0.50 than original 0.70. Internal flag for full re-price next Sunday.
Counter-narrativeIndustry may self-regulate via compounders catching contamination before a headline-grade incident
- 2026-04-22 04:04 UTC · Ra runread brief →65%-0.05· signal 58
WaPo April 15 feature seeds the narrative but covers regulation, not injuries/deaths. Medscape secret-shopper study demonstrates journalistic method exists. 12-58% contamination rate in unregulated products is the fuel. However: Cat 2 removal + reclassification to Cat 1 could paradoxically REDUCE risk by moving production to regulated 503A/B pharmacies. Dual-direction signal warrants modest downward revision. Prior re-price flag from Sunday acknowledged.
Counter-narrativeReclassification to Cat 1 may improve safety by channeling demand from gray-market to regulated compounders, reducing probability of headline incident
- 2026-04-22 10:52 UTC · Ra run· flaggedread brief →62%-0.03· signal 57
Second-pass (10:52 UTC). KEY DIVERGENCE from 15:30 run: FDA explicitly stated no spike in adverse events from compounded peptides. This is a strong negative signal the 15:30 run did not capture. Argues for 0.62 vs 15:30 run's 0.65 hold. Flagging for operator adjudication.
Counter-narrativeReclassification channels demand to regulated 503A/B compounders reducing gray-market share and incident probability; FDA reports no adverse event spike
- 2026-04-22 15:30 UTC · Ra runread brief →65%0· signal 58
Dual-direction signals cancel. ProPublica + Woodcock building investigative narrative infrastructure for safety backlash. But Cat 1 reclassification could reduce gray-market sourcing, paradoxically improving safety. No new actual incidents reported. Media is positioned to amplify whatever occurs — the journalistic template exists.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders, shrinking gray-market and reducing contamination incidents
- 2026-04-23 07:04 UTC · Ra runread brief →65%0· signal 58
No new incidents. FDA no-adverse-event-spike finding confirmed. Unresolved adjudication (0.62 vs 0.65) from April 22 persists — operator input needed.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing contamination and incident probability
- 2026-04-24 07:04 UTC · Ra runread brief →63%-0.02· signal 57
Resolving April 22 adjudication (0.62 vs 0.65). FDA no-adverse-event-spike signal captured in 10:52 run warrants acknowledgment. Cat 1 channeling paradox reduces gray-market risk. Settling at 0.63.
Counter-narrativeAdoption velocity increases absolute adverse events even as contamination rate may fall under Cat 1 channeling; ProPublica and WaPo have investigative templates ready
- 2026-04-25 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. Reclassification literature emphasizes USP 797/795 standards for regulated compounders. Research-use-only peptides still sold online. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination risk
- 2026-04-26 07:04 UTC · Ra runread brief →63%0· signal 57
1000+ adverse events on compounded GLP-1s by mid-2025 and GHRP-2 deaths documented. 8% endotoxin contamination in gray-market. But FDA says no spike from compounded peptides specifically. Dual-direction signals cancel. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination risk
- 2026-04-27 07:04 UTC · Ra runread brief →63%0· signal 57
Weekly review: no new adverse events. FDA confirmed no spike from compounded peptides. Dual-direction equilibrium holds (Cat 1 reduces gray-market risk; adoption velocity increases exposure). ProPublica/WaPo templates positioned but no named victim story. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-04-28 04:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. FDA no-spike finding stands. Research-use-only peptides still sold online. Media templates positioned but no trigger event. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-04-29 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. PMC immunogenicity paper and UVA Q&A are academic substrate not media catalysts. Journalistic templates positioned but no named victim. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-04-30 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. Immunogenicity review (PMC) reinforces academic safety substrate. Gray-market contamination rates unchanged. Journalistic templates positioned but no named victim. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-01 07:04 UTC · Ra runread brief →63%0· signal 58
Scientific American, STAT, and SAGE journal building narrative infrastructure. Pipeline: academic study → journalist interviews → major feature. No new adverse events. Trigger event still missing. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-02 07:04 UTC · Ra runread brief →63%0· signal 57
FDA 503B GLP-1 exclusion could push some outsourcing facilities to pivot into peptide compounding; marginal increase in contamination risk if lower-quality facilities enter peptide space. Speculative. No new adverse events. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination; FDA confirms no adverse event spike
- 2026-05-03 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. Partnership for Safe Medicines is new institutional actor in safety narrative — pharma-backed, currently focused on GLP-1s not peptides. Could pivot if PCAC opens peptide compounding. Journalistic templates remain positioned without trigger event. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-04 07:04 UTC · Ra runread brief →63%0· signal 58
NYT David Dodge covering peptides on Glossy podcast confirms journalistic infrastructure building. Beat reporters on podcasts typically precede major features by 2-6 months. SciAm feature adds substrate. But no new adverse events and FDA no-spike finding holds. Dual-direction signals cancel. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-05 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. No new investigative features. Journalistic templates positioned but trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-06 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. 503B exclusion rationale disclosed 455+ compounded semaglutide and 320+ compounded tirzepatide adverse events — not peptide-specific but establishes compounding-safety narrative template for post-PCAC media framing. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-07 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. No new investigative features. Journalistic templates positioned but trigger event absent. Dual-direction signals (adoption increases exposure; reclassification reduces contamination) cancel. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-08 07:04 UTC · Ra runread brief →63%0· signal 57
No new adverse events. No new investigative features. Journalistic infrastructure positioned but trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A/B compounders reducing gray-market contamination and headline incident probability
- 2026-05-09 07:04 UTC · Ra runread brief →63%0· signal 58
No new top-5 outlet feature. Eric Topol Substack peptide piece is named-voice leading indicator — historically fronts WSJ/NYT health features 6-12 months. ECRI/ISMP joint warning queues clinical-specialist trigger. Discourse build-phase intensifying. Trigger event still absent. Holding.
Counter-narrativeFDA enforcement of gray-market sellers tightens fast enough to prevent headline-grade incident before March 2027
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://erictopol.substack.com/p/the-peptide-craze
- https://theconversation.com/the-peptide-problem-hype-is-outrunning-the-evidence-280715
- 2026-05-10 07:04 UTC · Ra runread brief →63%0· signal 58
No new adverse events. PeptideJournal narrative distortion (Cat 2 removal framed as reclassification) could paradoxically increase gray-market sourcing if consumers misinterpret as full legalization. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated compounders reducing gray-market contamination and headline incident probability
- 2026-05-11 07:04 UTC · Ra runread brief →63%0· signal 58
No new adverse events. No new top-5 outlet features. 30% gray-market contamination rate unchanged. Discourse infrastructure building but trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-12 07:04 UTC · Ra runread brief →63%0· signal 58
No new adverse events. No new top-5 outlet features. Gray-market contamination rates unchanged. Discourse infrastructure building but trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-13 07:04 UTC · Ra runread brief →63%0· signal 58
No new adverse events. No new top-5 outlet features. Estrogen-patch-shortage pattern (FDA denies shortage while demand doubles) filed as analog for peptide demand-supply dynamics. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated compounders reducing gray-market contamination and headline incident probability
- 2026-05-14 07:04 UTC · Ra runread brief →65%+0.02· signal 60
ISMP and ECRI formal warnings plus LegitScript emerging-risk categorization escalate discourse infrastructure from researcher/media to institutional level. PBS political framing pre-builds backlash scaffold. +0.02 for category escalation without trigger event.
Counter-narrativeCat 1 reclassification channels demand to regulated compounders reducing gray-market contamination and headline incident probability
- https://www.medscape.com/viewarticle/wellness-peptides-lack-reliable-safety-information-watchdog-2026a1000fbf
- https://www.legitscript.com/high-risk-and-problematic-products/peptides-in-dietary-supplements-emerging-risk/
- https://www.pbs.org/newshour/health/fda-to-weigh-easing-limits-on-unproven-peptides-favored-by-rfk-jr-and-maha-supporters
- 2026-05-15 07:04 UTC · Ra runread brief →65%0· signal 60
No new adverse events. BSR Intelligence published institutional-grade peptide industry briefing with counterfeit risk coverage (paywalled). Discourse infrastructure building at institutional level. No trigger event. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-16 07:04 UTC · Ra runread brief →67%+0.02· signal 62
MedicalXpress reports AI methodology scanning 400000 Reddit posts for overlooked GLP-1 side effects — technique transfers directly to compounded peptides. Detection-channel signal: time between anonymous user complaint and citable adverse-event corpus collapsing. Preventive Medicine Daily pharmacovigilance analysis confirms arsenic 10x toxicity limits and lead contamination. +0.02 for detection-methodology institutionalization absent trigger event.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-17 07:04 UTC · Ra runread brief →70%+0.03· signal 67
ProPublica feature is tier-1 institutional safety escalation with 30-90 day documented downstream pickup window into named falsifier outlets. Combined with NPR May 6, UNSW academic paper, TikTok algorithmic suppression of peptide creators, and ProRx 15k-vial sterility recall. Trajectory accelerating. +0.03.
Counter-narrativeIf Cat 1 reclassification successfully channels demand to regulated 503A compounders, gray-market headline risk drops materially; ProPublica adjacent but not formally on the falsifier outlet list (NYT/WSJ/CNN/NPR/WaPo)
- https://www.propublica.org/article/peptide-safety-fda-compounding-pharmacies
- https://www.npr.org/2026/05/06/nx-s1-5812662/medicare-bridge-glp1-drugs-copay
- https://tucson.com/news/nation-world/business/personal-finance/article_780568ec-86c7-5705-9cd5-f2cec1a25276.html
- https://www.unsw.edu.au/newsroom/news/2026/04/injectable-peptides-anti-ageing-trend-safe-humans-evidence
- https://www.tiktok.com/discover/why-peptide-influencers-blocked
- 2026-05-18 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events or top-5 outlet features since yesterday's ProPublica +0.03 adjustment. Institutional safety discourse building at institutional level. Trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-19 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. JAMA VA study 35% higher NAION risk among GLP-1 users is parallel safety-litigation template for adjacent peptide class. Template signal not trigger. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-20 07:04 UTC · Ra runread brief →70%0· signal 67
BPC-157 at Google Trends peak (100) in April. 281%/459%/412% YoY growth Google/TikTok/Instagram. Discourse infrastructure in late build-phase (ECRI ISMP PBS ProPublica academic papers). Journalistic template complete but trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-21 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase. AbbVie Alora estrogen patch discontinuation filed as gray-market-template reference class. Template without trigger. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability
- 2026-05-22 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. BSR Intelligence peptide industry briefing (March-May 2026) confirms elevated counterfeit and contamination risk at baseline. TRIUMPH-1 dysesthesia creates collateral side-effects media frame but not directly peptide-related. Trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; ProPublica adjacent but not formally on the falsifier outlet list
- 2026-05-23 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Institutional template positioning stable at late build-phase month 2-3. TRIUMPH-1 dysesthesia (Day 2) conditions media genre but is not a trigger for peptide safety specifically. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; TRIUMPH-1 dysesthesia expands side-effects media frame but is branded GLP-1 not compounded peptide
- 2026-05-24 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. FDA confirms no spike from compounded peptides specifically. Institutional template positioning stable at late build-phase. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; 775+ compounded GLP-1 adverse events provide corpus but no peptide-specific named-victim event
- 2026-05-26 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase (ECRI ISMP LegitScript ProPublica PBS Topol). Trigger event absent. Dual-direction signals cancel. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events reported
- 2026-05-27 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. WaPo factory access is dual-use: validates peptide market (bearish) while positioning reporter for future safety investigation (bullish). Signals cancel. Discourse infrastructure stable at late build-phase. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events reported
- 2026-05-28 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. CNN April 2026 coverage is explainer mode not investigation. Discourse infrastructure stable at late build-phase. Trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events reported
- 2026-05-29 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. USADA BPC-157 prohibition creates doping-scandal angle as potential named-victim catalyst — speculative not probability-moving. Discourse infrastructure stable at late build-phase. Trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; USADA prohibition creates potential athlete-named-victim catalyst
- 2026-05-30 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase. Trigger event absent. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-05-31 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase. Trigger event absent. 304 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-01 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase. Trigger event absent. 303 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-02 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. Discourse infrastructure stable at late build-phase. Trigger event absent. 302 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events reported
- 2026-06-03 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. ADA week absorbs health media oxygen narrowing window for peptide safety features. Post-ADA and pre-PCAC late June is next plausible media window. 301 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-04 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. Precision Peptide 25K Rx/day 503A deal marginally channels demand toward regulated compounding, reducing gray-market exposure. ADA week absorbs health media oxygen. Post-ADA / pre-PCAC late June is next plausible media window. 300 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; Precision Peptide 503A deal confirms channeling thesis
- 2026-06-05 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. No new top-5 outlet features. ADA week absorbs health media oxygen narrowing window for peptide safety features. Post-ADA pre-PCAC late June is next plausible media window. 299 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-06 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. ADA Day 2 absorbs health media oxygen. Retatrutide TRIUMPH-1 presenting today 1:30 PM CDT — will dominate health news cycle through Monday narrowing window for peptide safety features. Post-ADA pre-PCAC late June remains next plausible media window. 298 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-07 07:04 UTC · Ra runread brief →70%0· signal 67
Weekly review. No new adverse events. ADA absorbed health media bandwidth June 5-8. Post-ADA pre-PCAC late June next plausible media window. ProPublica WaPo templates positioned no trigger event. Stoic: unactionable. 297 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-08 07:04 UTC · Ra runread brief →70%0· signal 67
Weekly review. No new adverse events. ADA concluded June 8 — post-ADA / pre-PCAC media window (June 9 - July 22) now open. Highest-probability period for peptide safety features. Stanford muscle-GLP-1 study bridges GLP-1 and peptide narratives culturally. ProPublica WaPo templates positioned no trigger event. Stoic: unactionable. 296 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-09 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. Post-ADA / pre-PCAC media window (June 9 - July 22) now open — highest-probability period for peptide safety features. Health media bandwidth freed from ADA coverage. PCAC deadline creates editorial urgency. 296 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-10 07:04 UTC · Ra runread brief →70%0· signal 67
No new adverse events. Post-ADA / pre-PCAC media window (June 9-July 22) now in Day 2 — highest-probability period for investigative peptide safety features. Preventive Medicine Daily gray-market pharmacovigilance analysis builds academic substrate. ProPublica WaPo templates positioned but no named-victim trigger event. 295 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination and headline incident probability; no new adverse events
- 2026-06-11 07:04 UTC · Ra runread brief →73%+0.03· signal 70
MATERIAL. DOJ criminal enforcement escalating: Tailor Made Compounding $1.79M forfeiture; Dr. Watkins indicted April 2026 selling peptides to 200+ patients; Paradigm Peptides guilty pleas Dec 2025; BioPeptide Labs charged; Peptide Sciences shut down March 2026; 50+ FDA warning letters 2024-2025. Historian: matches EVALI trajectory — DOJ indictments precede top-5 outlet features 3-12 months. Skeptic: charges are misbranding/fraud not patient harm — named-victim catalyst absent. Bayesian: court documents and named defendants provide institutional narrative infrastructure for ProPublica/WaPo templates already positioned. Post-ADA pre-PCAC media window open. +0.03.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but DOJ criminal enforcement creates institutional narrative infrastructure for investigative features even without named-victim catalyst
- https://www.amcdefenselaw.com/justice-watch/peptide-industry-federal-criminal-charges-2026
- https://www.stevenslee.com/health-law-observer-blog/indictment-of-osteopathic-physician-signals-shift-in-peptide-enforcement/
- https://peptidelaws.com/news/recent-doj-actions-against-illegal-peptide-distributors
- https://www.justice.gov/usao-ndin/united-states-v-matthew-kawa
- https://grokipedia.com/page/FDA_Enforcement_Actions_Against_Research_Peptide_Vendors_20252026
- 2026-06-12 07:04 UTC · Ra runread brief →73%0· signal 67
No new adverse events. Post-ADA pre-PCAC media window Day 4 of 44. DOJ enforcement infrastructure continues (Tailor Made Watkins Peptide Sciences). ProPublica WaPo templates positioned no trigger event. PeptideExaminer enforcement timeline confirms 50+ warning letters 2024-2025 with criminal referral escalation. 292 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but DOJ criminal enforcement creates institutional narrative infrastructure for investigative features even without named-victim catalyst
- 2026-06-13 07:04 UTC · Ra runread brief →73%0· signal 67
No new adverse events. Post-ADA pre-PCAC media window Day 5 of 44. NBC estrogen-patch story uses FDA-says-X-patients-say-Y template structurally identical to future peptide safety feature template. Template migration across health-journalism categories is a leading indicator. DOJ court documents (Tailor Made Watkins Peptide Sciences) provide named-defendant infrastructure. 290 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but DOJ criminal enforcement creates institutional narrative infrastructure for investigative features even without named-victim catalyst
- 2026-06-14 07:04 UTC · Ra runread brief →73%0· signal 68
Weekly review. No new adverse events. Nature published peptide craze feature creating academic-to-media citation pipeline. Post-ADA pre-PCAC media window Day 6 of 44. DOJ court documents (Tailor Made Watkins Peptide Sciences 50+ warnings) provide named-defendant infrastructure. TikTok +459% YoY accelerates amateur adoption increasing exposure. Dual-direction signal. 289 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but Nature engagement plus DOJ enforcement infrastructure creates narrative pipeline for investigative features
- https://www.nature.com/articles/d41586-026-01816-x
- https://www.glossy.co/beauty/injectable-peptide-therapy-went-mainstream-in-2025-priming-consumers-for-the-next-big-wave-in-wellness/
- https://www.amcdefenselaw.com/justice-watch/peptide-industry-federal-criminal-charges-2026
- https://www.propublica.org/article/peptide-safety-fda-compounding-pharmacies
- 2026-06-15 07:04 UTC · Ra runread brief →73%0· signal 68
Weekly review. No new adverse events. Lilly warning re fraudulent compounded tirzepatide (bacteria impurities incorrect structures) establishes branded-pharma-documents-contamination template. FDA 455+ semaglutide AERs 320+ tirzepatide AERs on record. Post-ADA pre-PCAC media window Day 7 of 44. 288 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but Lilly contamination warning plus 455+ semaglutide AE reports plus DOJ enforcement creates institutional narrative infrastructure
- 2026-06-16 07:04 UTC · Ra runread brief →73%0· signal 67
No new adverse events. Post-ADA pre-PCAC media window Day 9 of 44. DOJ enforcement infrastructure intact (Tailor Made Watkins Peptide Sciences 50+ warnings). Lilly contamination warning template established. 287 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but DOJ criminal enforcement creates institutional narrative infrastructure for investigative features even without named-victim catalyst
- 2026-06-17 07:04 UTC · Ra runread brief →73%0· signal 67
No new adverse events. LegitScript flagged peptides in supplements as emerging risk — compliance platform classifications cascade to Google Ads Facebook Visa/Mastercard policy. PBS frames PCAC as political. Post-ADA pre-PCAC media window Day 10 of 44. DOJ enforcement infrastructure intact. 286 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but LegitScript emerging-risk classification plus PBS political framing creates institutional narrative infrastructure for investigative features
- https://www.legitscript.com/high-risk-and-problematic-products/peptides-in-dietary-supplements-emerging-risk/
- https://www.pbs.org/newshour/health/fda-to-weigh-easing-limits-on-unproven-peptides-favored-by-rfk-jr-and-maha-supporters
- https://www.peptidedeck.com/blog/are-peptides-safe-2026-mainstream-science-review
- 2026-06-18 07:04 UTC · Ra runread brief →75%+0.02· signal 70
Chainalysis quantifies gray-market peptide economy at $100M+ annual run rate Q1 2026 $32M +159% QoQ. Fortune identifies looksmaxxing demographic young males buying via crypto zero medical supervision. Bloomberg gold rush feature. Structural analog to EVALI vaping demographic pattern. Higher-risk population expands contamination exposure base rate. Moving +0.02 to 0.75. 285 days to resolution.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but $100M+ crypto gray-market with looksmaxxing demographic expands unregulated exposure faster than regulatory channel shift
- 2026-06-19 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. ECRI and ISMP joint white paper (May 2026) now fully surfaced: two most credible US patient safety watchdogs formally warning that compounded peptide market has outpaced safety data. BPC-157 35/36 studies in animals; gray-market purity 5-75% with arsenic and lead. These are the SAME organizations that flagged compounding risks pre-NECC 2012. Creates formal we-warned-you timestamp for investigative journalism. Signal partially priced yesterday via Medscape search result; institutional provenance is the new data point. 284 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but ECRI/ISMP institutional warning plus $100M+ crypto gray-market with looksmaxxing demographic expands unregulated exposure faster than regulatory channel shift
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://home.ecri.org/blogs/ecri-news/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn
- https://www.medscape.com/viewarticle/wellness-peptides-lack-reliable-safety-information-watchdog-2026a1000fbf
- 2026-06-20 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. ECRI/ISMP and Chainalysis gray-market fully priced. Post-ADA pre-PCAC media window Day 13 of 44. 503B comment-period deadline June 29 may trigger media round-up on compounding safety. DOJ enforcement infrastructure intact. 283 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but ECRI/ISMP institutional warning plus $100M+ crypto gray-market with looksmaxxing demographic expands unregulated exposure faster than regulatory channel shift
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://fortune.com/2026/06/04/peptides-crypto-looksmaxxing-economy-chainalysis-report-100-million/
- https://www.bloomberg.com/features/2026-peptide-legalization-gold-rush/
- 2026-06-21 07:04 UTC · Ra runread brief →75%0· signal 70
Weekly review. No new adverse events. Chainalysis deeper-read details: Chinese manufacturers pivoted from fentanyl and amphetamine precursors to peptide production — same supply chain that fueled opioid crisis now producing injectables. Per-buyer testing expenditure dropped 88% ($67 to $8) consumers injecting untested products. Refinements of already-priced June 18 data not independent signals. Post-ADA pre-PCAC media window Day 14 of 44. 503B comment deadline June 29 may trigger media round-up. 282 days to resolution.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but fentanyl-precursor supply chain pivot to peptide manufacturing plus 88% per-buyer testing expenditure collapse expands unregulated exposure
- https://fortune.com/2026/06/04/peptides-crypto-looksmaxxing-economy-chainalysis-report-100-million/
- https://www.chainalysis.com/blog/gray-market-peptide-crypto-boom/
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- 2026-06-22 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. 503B comment deadline June 29 in 7 days — FDA press release cites 455+ adverse events from compounded semaglutide and 320+ from compounded tirzepatide. Comment-period coverage may spill over to peptide safety narrative. ECRI/ISMP and Chainalysis fully priced. Post-ADA pre-PCAC media window Day 15 of 44. 281 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but fentanyl-precursor supply chain pivot plus 88% per-buyer testing expenditure collapse expands unregulated exposure
- https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- https://fortune.com/2026/06/04/peptides-crypto-looksmaxxing-economy-chainalysis-report-100-million/
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- 2026-06-23 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. 503B comment deadline June 29 in 6 days — comment-period coverage may spill into peptide safety narrative. Peptide Sciences voluntary shutdown (March 2026) removed one major gray-market vendor but scatter-effects demand to remaining sellers. ECRI/ISMP and Chainalysis fully priced. Post-ADA pre-PCAC media window Day 16 of 44. 280 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but fentanyl-precursor supply chain pivot plus 88% per-buyer testing expenditure collapse expands unregulated exposure faster than regulatory channel shift
- https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://peptidesexplorer.com/blog/peptide-sciences-shut-down
- 2026-06-24 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Cumulative compounded GLP-1 adverse events 775+ (455 semaglutide + 320 tirzepatide) — consolidation of prior figures not new disclosure. Post-ADA pre-PCAC media window Day 17 of 44. 503B comment-period close June 29 may trigger safety-adjacent coverage. ECRI/ISMP and Chainalysis fully priced. 279 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but fentanyl-precursor supply chain pivot plus 88% per-buyer testing expenditure collapse expands unregulated exposure faster than regulatory channel shift
- https://www.peptidejournal.org/legal/fda-peptide-regulation-complete-2025-2026-timeline
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://fortune.com/2026/06/04/peptides-crypto-looksmaxxing-economy-chainalysis-report-100-million/
- 2026-06-25 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 18 of 44. 503B comment-period close June 29 in 4 days — FDA proposal cites cumulative 775+ compounded GLP-1 adverse events. Comment-period coverage may spill into broader compounding safety narrative. ECRI/ISMP and Chainalysis fully priced. 278 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but 503B comment-period close June 29 citing 455+ semaglutide AERs 320+ tirzepatide AERs may trigger safety-adjacent coverage
- https://www.fda.gov/news-events/press-announcements/fda-proposes-exclude-semaglutide-tirzepatide-and-liraglutide-503b-bulks-list
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12927500/
- 2026-06-26 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 19 of 44. 503B comment-period close June 29 in 3 days. PeptideDeck safety review and Pharmacy Times coverage joining the institutional-concern content layer but adding no new data points. ECRI/ISMP and Chainalysis fully priced. 277 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but 503B comment-period close June 29 citing 775+ compounded GLP-1 adverse events may trigger safety-adjacent coverage amplifying broader compounding scrutiny
- https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://www.peptidedeck.com/blog/are-peptides-safe-2026-mainstream-science-review
- 2026-06-27 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 20 of 44. 503B comment-period EXTENDED to July 30 (from June 29). This concentrates two compounding-safety media events — PCAC July 23-24 and 503B close July 30 — into a single week rather than spreading across June-July. May amplify safety-adjacent coverage. ECRI/ISMP and Chainalysis fully priced. 276 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but 503B extension to July 30 concentrates PCAC and 503B-close media events into single week amplifying safety-adjacent coverage
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- https://www.prnewswire.com/news-releases/patients-using-wellness-peptides-have-no-reliable-information-about-whether-they-are-safe-or-effective-ecri-and-ismp-warn-302763107.html
- https://fortune.com/2026/06/04/peptides-crypto-looksmaxxing-economy-chainalysis-report-100-million/
- 2026-06-28 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 21 of 44. 503B extension to July 30 creates calendar concentration: PCAC July 23-24 and 503B close July 30 within same week. Two compounding-safety media events in 7 days creates amplification structure for investigative coverage. Lilly fraudulent tirzepatide warning and FDA 775+ adverse event citation remain shelf-ready for journalists. 275 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but 503B-PCAC same-week concentration July 23-30 amplifies compounding safety media coverage
- https://www.pharmexec.com/view/federal-judge-blocks-rfk-vaccine-advisory-council-appointments
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- https://sherwood.news/culture/the-peptide-gold-rush-how-impending-deregulation-could-supercharge-a-shadow/
- 2026-06-29 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 22 of 44. PCAC-503B concentration week July 23-30 creates amplification structure. FDA 80+ telehealth warning letters plus Gram Peptides warning March 2026 provide shelf-ready journalist material. 274 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
- https://www.federalregister.gov/documents/2026/06/26/2026-12937/list-of-bulk-drug-substances-for-which-there-is-a-clinical-need-under-section-503b-of-the-federal
- 2026-06-30 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. PCAC oral presentation deadline today — filing volume signals advocacy intensity and media attention. PCAC-503B concentration week July 23-30 creates dual-hook amplification for investigative journalism. 30% contamination rate from independent testing confirmed by BSCG and multiple clinic sources. 273 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- 2026-07-01 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Bridge launch creates latent narrative hook: Medicare covers GLP-1s at $50 but not peptides — potential media angle for why patients turn to gray market. PCAC-503B concentration week July 23-30 creates dual-hook amplification. 272 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- 2026-07-02 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events. Post-ADA pre-PCAC media window Day 25 of 44. PCAC-503B concentration week July 23-30 creates dual-hook amplification. Estrogen patch shortage 44% fill difficulty across 8000 women validates supply-shortage-to-gray-market pipeline pattern applicable to peptides. 271 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- 2026-07-03 07:04 UTC · Ra runread brief →75%0· signal 70
No new US adverse events. Medsafe NZ issued consumer advisory May 21 2026 warning about significant health and legal risks of unapproved peptide products — international regulatory bodies now publicly flagging safety adding journalistic basis for US investigative coverage. PCAC-503B concentration week July 23-30 creates dual-hook amplification structure. 270 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- 2026-07-04 07:04 UTC · Ra runread brief →75%0· signal 70
No new US adverse events. July 4 holiday. PCAC-503B concentration week in 19 days creates dual-hook editorial structure. Medsafe NZ advisory continues providing international regulatory precedent. 269 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; but PCAC-503B same-week concentration July 23-30 amplifies compounding safety media coverage
- 2026-07-05 07:04 UTC · Ra runread brief →75%0· signal 72
PCAC conflict-of-interest narrative (AP NBC NPR) creates pre-built editorial framework for peptide safety investigative journalism. FDA staff briefing citing insufficient safety data provides source material. PCAC-503B concentration week July 23-30 creates dual-hook editorial calendar. No new US adverse events. 268 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC conflict-of-interest narrative may exhaust media appetite for peptide coverage reducing safety-incident likelihood
- 2026-07-06 07:04 UTC · Ra runread brief →75%0· signal 72
FDA warning letter to Gram Peptides March 31 2026 adds concrete enforcement action to investigative-journalism source material. PCAC-503B concentration week July 23-30 creates dual-hook editorial calendar. Medsafe NZ advisory provides international precedent. No new US adverse events. 267 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC conflict-of-interest narrative exhausts media appetite for peptide coverage
- https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/gram-peptides-721806-03312026
- https://abcnews.com/Health/wireStory/fda-panel-peptides-include-experts-promote-unproven-chemicals-134321957
- https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026
- 2026-07-07 07:04 UTC · Ra runread brief →75%0· signal 70
No new adverse events; post-ADA pre-PCAC media window day 30 of 44; STAT conflict-of-interest article is institutional narrative infrastructure but not a safety incident; PCAC-503B calendar concentration July 23-30 remains amplification structure; 267 days to resolution; holding 0.75
Counter-narrativeIf PCAC recommends Cat 1 for any peptides the resulting demand surge through regulated channels may paradoxically reduce safety incidents by channeling users away from gray-market sources
- 2026-07-08 07:04 UTC · Ra runread brief →75%0· signal 72
775+ cumulative compounded peptide/GLP-1 adverse event reports; no new headline-grade incident; PCAC meeting July 23 may serve as editorial hook for safety journalism — FDA briefing materials cite 40% contamination rate; PCAC-503B concentration week July 23-30 remains amplification window; 266 days to resolution; holding 0.75
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC conflict-of-interest narrative may exhaust media appetite for peptide safety coverage
- 2026-07-10 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. PCAC-503B concentration week July 23-30 in 13 days creates dual-hook editorial window. 775+ cumulative AE reports. FDA briefing materials citing 40% contamination rate available to journalists covering hearing. 264 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC conflict-of-interest narrative may exhaust media appetite for safety coverage
- 2026-07-11 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. PCAC-503B concentration week July 23-30 in 12 days creates dual-hook editorial window. 775+ cumulative AE reports. FDA briefing materials citing 40% contamination available to journalists. 263 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC conflict-of-interest narrative may exhaust media appetite for safety coverage
- 2026-07-12 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. Independent analysis confirms 30% grey-market contamination rate. PCAC week July 23-30 creates dual-hook editorial window for journalists encountering 40% contamination and 775+ AE in briefing materials. 263 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC week editorial window may exhaust media appetite
- 2026-07-13 07:04 UTC · Ra runread brief →75%0· signal 72
FDA briefing docs now public citing 40% contamination and unassessed immunogenicity accessible to journalists. Bloomberg peptide-startup-race amplifies media attention. PCAC week July 23-30 dual-hook editorial window. No new US adverse events. 262 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; media attention fatigue from PCAC cycle may exhaust safety-story appetite
- 2026-07-14 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. Regulatory convergence week July 23-30 PCAC plus 503B deadline concentrates media attention on compounding safety. FDA briefing docs with 40% contamination accessible to journalists. 260 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC plus 503B convergence week media attention may exhaust safety-story appetite
- 2026-07-15 07:04 UTC · Ra runread brief →75%0· signal 72
PSM formal filing adds institutional-grade source material to public record: FDA warning letters to Chinese API producers for sterility violations TB-500 tumor acceleration data 78% complications linked to contamination. Citation-ready for journalists covering PCAC week. No new US adverse events. 259 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC plus 503B convergence week media attention may exhaust safety-story appetite
- 2026-07-16 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. Hims consumer peptide campaign increases mainstream awareness and journalist attention surface. Regulatory convergence week July 23-30 PCAC plus 503B deadline. PSM citation-ready filing accessible. 258 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; Hims consumer campaign may paradoxically increase journalism surface area
- https://www.benzinga.com/analyst-stock-ratings/price-target/26/07/60225352/hims-hers-healths-peptide-opportunity-tempered-by-fda-recommendation-says-analyst
- https://www.bscg.org/blogs/single/whats-changing-with-peptide-regulation-in-2026
- https://stocktwits.com/news-articles/markets/equity/hims-peptides-campaign-key-fda-meeting/cZmzKDjR7oN
- 2026-07-17 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. Regulatory convergence week July 23-30 creates concentrated editorial window. PSM citation-ready filing accessible. FDA briefing docs with 40% contamination. 257 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC plus 503B convergence week media attention may exhaust safety-story appetite
- 2026-07-18 07:04 UTC · Ra runread brief →75%0· signal 72
No new US adverse events. Regulatory convergence week July 23-30 creates concentrated editorial window. PSM citation-ready filing with 78% complications linked to contamination. FDA briefing docs with 40% contamination. 256 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC plus 503B convergence week media attention may exhaust safety-story appetite
- 2026-07-19 07:04 UTC · Ra runread brief →75%0· signal 72
FDA May 2026 import alert on 38 foreign API manufacturers following 14-month MedWatch investigation Q3 2025-Q1 2026 confirmed. Hangzhou Yiqi warning letter April 2026. PSM cites 78% complications linked to contamination. Regulatory convergence week July 23-30 concentrates editorial attention. No top-5 outlet major feature yet. 255 days to resolution. Holding.
Counter-narrativeCat 1 reclassification channels demand to regulated 503A compounders reducing gray-market contamination; PCAC plus 503B convergence week media attention may exhaust safety-story appetite
- 2026-07-20 07:04 UTC · Ra runread brief →75%0· signal 72
FDA background materials cite insufficient safety data plus unassessed immunogenicity across all 7 — citation-ready ammunition for an investigative feature during the July 23-30 convergence week. No top-5 outlet feature yet. 254 days to resolution. Holding.
Counter-narrativeCat 1 denials channel demand toward regulated compounders and the PCAC convergence week may exhaust safety-story appetite before a top-5 feature lands
- 2026-07-21 07:04 UTC · Ra runread brief →75%0· signal 74
Concrete new ammunition: FDA FAERS records a life-threatening incident and a hospitalization linked to BPC-157 contamination; April 2026 Hangzhou Yiqi warning letter/import alert; independent testing found some batches <50% labeled compound. Combined with FDA background materials citing unassessed immunogenicity across all 7, this is citation-ready for an investigative feature during the July 23-30 convergence week. No top-5 outlet feature yet. 253 days to resolution. Holding.
Counter-narrativeA Cat 1 grant channeling demand to regulated 503A compounders plus convergence-week story fatigue could still delay a top-5 feature past March 2027
- 2026-07-22 07:04 UTC · Ra runread brief →75%0· signal 74
Forbes July 21 growing-public-health-challenge piece adds a fresh skeptical Tier-2 feature but is not a top-5 outlet. FAERS BPC-157 contamination + convergence week July 23-30 concentrate editorial attention; no top-5 major feature yet. 252 days to resolution. Holding.
Counter-narrativeA Cat 1 grant channeling demand to regulated 503A compounders plus convergence-week story fatigue could delay a top-5 outlet feature past March 2027.
- https://www.forbes.com/sites/omerawan/2026/07/21/fdas-review-of-peptides-signals-a-growing-public-health-challenge--separating-science-from-hype/
- https://www.safemedicines.org/2026/07/five-reasons-bulk-peptides.html
- https://www.statnews.com/2026/02/03/bpc-157-peptide-science-safety-regulatory-questions/
- 2026-07-23 04:05 UTC · Ra runread brief →75%0· signal 74
Convergence-week coverage intensifying (Fortune Jul 20, Forbes Jul 21, NPR-affiliate WWNO Jul 22) but still no top-5 national investigative feature on injuries/contamination/deaths. FAERS BPC-157 hospitalization + Apr 2026 import alerts remain citation-ready. 252 days to resolution. Holding.
Counter-narrativeCat 1 denials channel demand to regulated 503A compounders and convergence-week fatigue could delay a top-5 injury feature past March 2027.
- https://www.wwno.org/npr-news/2026-07-22/peptides-get-their-regulatory-closeup
- https://fortune.com/2026/07/20/the-fda-peptide-vote-could-create-telehealths-next-multibillion-dollar-market-telehealth-hims-ro-glp1-ozempic-injectables/
- https://www.forbes.com/sites/omerawan/2026/07/21/fdas-review-of-peptides-signals-a-growing-public-health-challenge--separating-science-from-hype/
- 2026-07-24 04:04 UTC · Ra runread brief →75%0· signal 76
Vote generated a Tier-1 coverage wave (STAT/Time/Hill/ABC) flagging FAERS BPC-157 adverse events, but still no top-5 national injury/contamination feature; legitimization cuts both ways. Hold 0.75, 250 days out.
Counter-narrativeLegitimization could route demand to regulated 503A compounders with better QC, reducing gray-market incident risk even as overall exposure rises.
- https://www.statnews.com/2026/07/23/fda-panel-okays-peptides-compound-pharmacies-bpc-157-kpv/
- https://time.com/article/2026/07/23/fda-committee-peptides/
- https://thehill.com/homenews/5987510-fda-committee-votes-peptides/
- https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026
- 2026-07-25 04:04 UTC · Ra runread brief →75%0· signal 76
Convergence-week coverage continues (TechTimes gray-market legal-limbo Jul 23, Regenexx contamination explainer surfacing endotoxin/heavy-metal/<50%-label findings) but still no top-5 national injury/contamination/deaths feature. FAERS BPC-157 adverse events remain citation-ready. 249 days to resolution. Holding.
Counter-narrativeLegitimization could route demand to regulated 503A compounders with better QC, muting gray-market incident risk even as overall exposure rises.
- https://www.techtimes.com/articles/321365/20260723/gray-market-peptide-users-face-legal-limbo-fda-scientists-oppose-bpc-157-vote.htm
- https://newregenortho.com/the-hidden-risks-of-bpc%E2%80%91157-what-patients-need-to-know-about-contamination-and-safety/
- https://www.raps.org/resource/fda-advisory-committee-backs-two-controversial-peptides.html
- 2026-07-26 04:04 UTC · Ra runread brief →75%0· signal 76
Held. Documented harm rising (43% lab-failure per Janoshik/thepeptidelist; FDA warning letters citing life-threatening infections; Forbes growing-public-health-challenge) but still no top-5 outlet injury/contamination/death feature; NPR covered the vote, not injuries. 248 days out. Loosening cuts both ways (fewer gray-market vs more mainstream users) -- net neutral.
Counter-narrativePCAC loosening channels demand to regulated 503A compounders, potentially reducing gray-market contamination and the injury-feature trigger; convergence-week attention may exhaust editorial appetite.
- 2026-07-27 04:15 UTC · Ra run· flaggedread brief →90%+0.15· signal 88
Material: WaPo published a July 24 investigation (states scrambling to protect consumers; gaping regulatory holes for medspas/peptides) -- a top-5 named outlet -- alongside NYT rebuke-of-FDA-scientists coverage, NBC Washington 30%-of-vials contamination lab finding, and Fortune endotoxin piece. Moves 0.75->0.90. FLAGGED for operator: verify the WaPo investigation qualifies against the injuries/contamination/deaths criteria; if yes resolve TRUE, ~8mo before the 2027-03-31 horizon.
Counter-narrativeThe WaPo piece frames the peptide boom as a regulatory-holes/consumer-protection investigation rather than a narrow injuries/deaths feature, so the operator may judge it short of the injuries/contamination/deaths bar.
- https://www.washingtonpost.com/health/2026/07/24/peptide-boom-has-states-scrambling-protect-consumers-post-investigation-finds/
- https://www.usnews.com/news/health-news/articles/2026-07-24/fda-advisers-dismiss-safety-warnings-back-four-peptide-treatments
- https://www.nbcwashington.com/news/health/doctors-flag-risks-contamination-as-fda-panel-weighs-loosening-restrictions/4133521/
- https://fortune.com/2026/07/23/peptides-endotoxin-contamination-fda-panel-conflicts/
- 2026-07-28 04:05 UTC · Ra run· flaggedread brief →90%0· signal 88
Held 0.90. Verification confirms the WaPo July 24 piece is a systemic regulatory-holes/consumer-protection investigation (states scrambling; medspas under-inspected; peptides unstudied) rather than a narrow injuries/contamination/deaths feature; no NEW top-5 injury feature landed today. Standing operator-verify flag persists: if the WaPo investigation clears the injuries/contamination/deaths bar resolve TRUE ~8mo early (Brier 0.01); if judged short, contamination base rates keep a qualifying feature highly likely before 2027-03-31. Augur note: WaPo spun up a wp-intelligence peptide-beat brief same day, raising odds of a follow-on injuries-specific feature. 246 days to horizon.
Counter-narrativeLegitimization routes demand to regulated 503A compounders with better QC, and the WaPo regulatory-holes framing may be judged short of the injuries/contamination/deaths bar with editorial appetite exhausted post-convergence-week.
- https://www.washingtonpost.com/health/2026/07/24/peptide-boom-has-states-scrambling-protect-consumers-post-investigation-finds/
- https://www.washingtonpost.com/wp-intelligence/health-brief/2026/07/24/health-brief-peptide-boom-outpaces-regulators/
- https://www.npr.org/2026/07/22/nx-s1-5902329/peptides-fda-compounding
- https://www.usnews.com/news/health-news/articles/2026-07-24/fda-advisers-dismiss-safety-warnings-back-four-peptide-treatments
- 2026-07-29 04:20 UTC · Ra runread brief →87%-0.03· signal 86
Trimmed 0.90 to 0.87 on a previously-unlogged deflator. ProPublica documented two women intubated after peptide injections at RAADFest (Jul 2025) and Nevada Pharmacy Board fines (Mar 2026); that raw material has been public ~12 months and no top-5 outlet ran the injuries feature even through the Jul 23-24 vote cycle, when WaPo chose the regulatory-holes frame instead. Nevada board could not obtain the product to test, so no causal case series exists. Offsetting: forecast wording is disjunctive (injuries OR contamination OR deaths), the NBC 30%-of-vials lab finding shows the contamination leg is live at national scale, WaPo has a standing peptide beat, and 245 days remain. Skeptic ~0.78 vs Bayesian 0.87 = 0.09, under threshold; mechanical flag clears but the standing operator decision on the WaPo Jul 24 investigation remains OPEN.
Counter-narrativeThe prestige-press frame for peptides is systemic-regulatory, not injuries-narrative -- a documented near-fatal injury cluster has sat unused for 12 months, and no causal case series exists because the product was never recovered for testing.
- https://www.propublica.org/article/peptide-injections-raadfest-rfk-jr
- https://www.propublica.org/article/raadfest-peptide-injections-nevada-fines
- https://www.mmm-online.com/news/raadfest-peptide-injections-nevada-fines/
- https://www.nbcwashington.com/news/health/doctors-flag-risks-contamination-as-fda-panel-weighs-loosening-restrictions/4133521/
- 31 Mar 2027 · resolves
245 days remaining. Re-evaluated each dawn by the council.
Sources at creation
- https://www.unsw.edu.au/newsroom/news/2026/04/injectable-peptides-anti-ageing-trend-safe-humans-evidence
- https://www.npr.org/2026/02/23/nx-s1-5716162/peptides-science-muscle-growth-longevity-wellness
- FDA testing 40 percent contamination / 25 percent undisclosed ingredient stats
Sources cited in subsequent Ra runs appear in each trajectory entry above.
Forecasts are never deleted; they are resolved. The log is the track record, and the track record is the moat.